Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement von Kronenberg, Florian, Mora, Samia, Stroes, Erik S G, Ference, Brian A, Arsenault, Benoit J, Berglund, Lars, Dweck, Marc R, Koschinsky, Marlys, Lambert, Gilles, Mach, François, McNeal, Catherine J, Moriarty, Patrick M, Natarajan, Pradeep, Nordestgaard, Børge G, Parhofer, Klaus G, Virani, Salim S, von Eckardstein, Arnold, Watts, Gerald F, Stock, Jane K, Ray, Kausik K, Tokgözoğlu, Lale S, Catapano, Alberico L

Volltext

Familial Hypercholesterolemia JACC Focus Seminar 4/4 von Brandts, Julia, Ray, Kausik K.

Volltext

Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care von Ray, Kausik K

Volltext

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Athero... von Ference, Brian A, Ginsberg, Henry N, Graham, Ian, Ray, Kausik K, Packard, Chris J, Bruckert, Eric, Hegele, Robert A, Krauss, Ronald M, Raal, Frederick J, Schunkert, Heribert, Watts, Gerald F, Borén, Jan, Fazio, Sergio, Horton, Jay D, Masana, Luis, Nicholls, Stephen J, Nordestgaard, Børge G, van de Sluis, Bart, Taskinen, Marja-Riitta, Tokgözoglu, Lale, Landmesser, Ulf, Laufs, Ulrich, Wiklund, Olov, Stock, Jane K, Chapman, M John, Catapano, Alberico L

Volltext

Novel and future lipid-modulating therapies for the prevention of cardiovascular disease von Brandts, Julia, Ray, Kausik K.

Volltext

Low Density Lipoprotein Cholesterol–Lowering Strategies and Population Health: Time to Move to a Cumulative Exposure Model von Brandts, Julia, Ray, Kausik K.

Volltext

Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? von Khunti, Kamlesh, Kosiborod, Mikhail, Ray, Kausik K.

Volltext

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol von Ray, Kausik K, Bays, Harold E, Catapano, Alberico L, Lalwani, Narendra D, Bloedon, LeAnne T, Sterling, Lulu R, Robinson, Paula L, Ballantyne, Christie M

Volltext

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia von Raal, Frederick J, Kallend, David, Ray, Kausik K, Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J, Curcio, Danielle, Jaros, Mark J, Leiter, Lawrence A, Kastelein, John J.P

Volltext

Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options von Ray, Kausik K, Corral, Pablo, Morales, Enrique, Nicholls, Stephen J

Volltext

Cholesterol-Lowering Agents: Statins—For Everyone? von Hadjiphilippou, Savvas, Ray, Kausik K

Volltext

Professor Rodolfo Paoletti (1932–2021) von Ray, Kausik K.

Volltext

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosi... von Borén, Jan, Chapman, M John, Krauss, Ronald M, Packard, Chris J, Bentzon, Jacob F, Binder, Christoph J, Daemen, Mat J, Demer, Linda L, Hegele, Robert A, Nicholls, Stephen J, Nordestgaard, Børge G, Watts, Gerald F, Bruckert, Eric, Fazio, Sergio, Ference, Brian A, Graham, Ian, Horton, Jay D, Landmesser, Ulf, Laufs, Ulrich, Masana, Luis, Pasterkamp, Gerard, Raal, Frederick J, Ray, Kausik K, Schunkert, Heribert, Taskinen, Marja-Riitta, van de Sluis, Bart, Wiklund, Olov, Tokgozoglu, Lale, Catapano, Alberico L, Ginsberg, Henry N

Volltext

The global diagnostic network: what can we learn from half a billion lipid measurements between 2018 and 2020? von Barkas, Fotios, Ray, Kausik K

Volltext

Bempedoic Acid to Lower LDL Cholesterol - Safety and Efficacy REPLY von Ray, Kausik K.

Volltext

Mendelian Randomization Study of ACLY and Cardiovascular Disease von Ference, Brian A, Ray, Kausik K, Catapano, Alberico L, Ference, Thatcher B, Burgess, Stephen, Neff, David R, Oliver-Williams, Clare, Wood, Angela M, Butterworth, Adam S, Di Angelantonio, Emanuele, Danesh, John, Kastelein, John J.P, Nicholls, Stephen J

Volltext

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies von Annemans, Lieven, Packard, Chris J, Briggs, Andrew, Ray, Kausik K

Volltext

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials von Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark J, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Lawrence, David, Friedman, Andrew, Garcia Conde, Lorena, Wright, R Scott

Volltext

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol von Ray, Kausik K, Wright, R. Scott, Kallend, David, Koenig, Wolfgang, Leiter, Lawrence A, Raal, Frederick J, Bisch, Jenna A, Richardson, Tara, Jaros, Mark, Wijngaard, Peter L.J, Kastelein, John J.P

Volltext

Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges von Nishikido, Toshiyuki, Ray, Kausik K.

Volltext